Latest filing published 30 Sept 2022 for Royalty Pharma plc, €4.2M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by James F. Reddoch on record concern Royalty Pharma plc, in the capacity of senior executive. In total, 11 filings cover trades dated from 7 May 2021 to 28 September 2022.
Sales make up the whole of the open-market record (10 sales, €21.0M). Since January 2022: no purchases and 4 sales on the market.
Most recently, on 30 September 2022, the filings show an open-market sale worth €4.2M in Royalty Pharma plc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations